Y-mAbs Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2019 to Q2 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Y-mAbs Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2019 to Q2 2025.
  • Y-mAbs Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2025 was 30.2 %, a 6.87% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2025 30.2 -2.23 -6.87% Jun 30, 2025
Q1 2025 34.7 +8.2 +30.9% Mar 31, 2025
Q4 2024 34.1 +6.79 +24.9% Dec 31, 2024
Q3 2024 33.1 +5 +17.8% Sep 30, 2024
Q2 2024 32.5 +3.23 +11.1% Jun 30, 2024
Q1 2024 26.5 -2.32 -8.04% Mar 31, 2024
Q4 2023 27.3 +0.5 +1.87% Dec 31, 2023
Q3 2023 28 +4.46 +18.9% Sep 30, 2023
Q2 2023 29.2 +10.2 +53.8% Jun 30, 2023
Q1 2023 28.9 +13.5 +87.3% Mar 31, 2023
Q4 2022 26.8 +14.3 +114% Dec 31, 2022
Q3 2022 23.6 +10.7 +83.6% Sep 30, 2022
Q2 2022 19 +4.79 +33.7% Jun 30, 2022
Q1 2022 15.4 -0.22 -1.41% Mar 31, 2022
Q4 2021 12.5 -4.6 -26.9% Dec 31, 2021
Q3 2021 12.9 -0.38 -2.87% Sep 30, 2021
Q2 2021 14.2 +1.8 +14.5% Jun 30, 2021
Q1 2021 15.6 +3.02 +24% Mar 31, 2021
Q4 2020 17.1 +4.11 +31.7% Dec 31, 2020
Q3 2020 13.2 -0.09 -0.68% Sep 30, 2020
Q2 2020 12.4 +2.05 +19.8% Jun 30, 2020
Q1 2020 12.6 Mar 31, 2020
Q4 2019 13 Dec 31, 2019
Q3 2019 13.3 Sep 30, 2019
Q2 2019 10.4 Jun 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.